Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
1.
Int J Cancer ; 151(7): 1033-1046, 2022 10 01.
Article in English | MEDLINE | ID: mdl-35579976

ABSTRACT

Previous studies had limited power to assess the associations of testosterone with aggressive disease as a primary endpoint. Further, the association of genetically predicted testosterone with aggressive disease is not known. We investigated the associations of calculated free and measured total testosterone and sex hormone-binding globulin (SHBG) with aggressive, overall and early-onset prostate cancer. In blood-based analyses, odds ratios (OR) and 95% confidence intervals (CI) for prostate cancer were estimated using conditional logistic regression from prospective analysis of biomarker concentrations in the Endogenous Hormones, Nutritional Biomarkers and Prostate Cancer Collaborative Group (up to 25 studies, 14 944 cases and 36 752 controls, including 1870 aggressive prostate cancers). In Mendelian randomisation (MR) analyses, using instruments identified using UK Biobank (up to 194 453 men) and outcome data from PRACTICAL (up to 79 148 cases and 61 106 controls, including 15 167 aggressive cancers), ORs were estimated using the inverse-variance weighted method. Free testosterone was associated with aggressive disease in MR analyses (OR per 1 SD = 1.23, 95% CI = 1.08-1.40). In blood-based analyses there was no association with aggressive disease overall, but there was heterogeneity by age at blood collection (OR for men aged <60 years 1.14, CI = 1.02-1.28; Phet  = .0003: inverse association for older ages). Associations for free testosterone were positive for overall prostate cancer (MR: 1.20, 1.08-1.34; blood-based: 1.03, 1.01-1.05) and early-onset prostate cancer (MR: 1.37, 1.09-1.73; blood-based: 1.08, 0.98-1.19). SHBG and total testosterone were inversely associated with overall prostate cancer in blood-based analyses, with null associations in MR analysis. Our results support free testosterone, rather than total testosterone, in the development of prostate cancer, including aggressive subgroups.


Subject(s)
Prostatic Neoplasms , Sex Hormone-Binding Globulin , Biomarkers , Humans , Male , Mendelian Randomization Analysis , Prostate , Prostatic Neoplasms/epidemiology , Prostatic Neoplasms/genetics , Risk Factors , Sex Hormone-Binding Globulin/analysis , Testosterone
2.
PLoS One ; 12(12): e0187741, 2017.
Article in English | MEDLINE | ID: mdl-29281666

ABSTRACT

INTRODUCTION: Sex hormones have been implicated in the etiology of a number of diseases. To better understand disease etiology and the mechanisms of disease-risk factor associations, this analysis aimed to investigate the associations of anthropometric, sociodemographic and behavioural factors with a range of circulating sex hormones and sex hormone-binding globulin. METHODS: Statistical analyses of individual participant data from 12,330 male controls aged 25-85 years from 25 studies involved in the Endogenous Hormones Nutritional Biomarkers and Prostate Cancer Collaborative Group. Analysis of variance was used to estimate geometric means adjusted for study and relevant covariates. RESULTS: Older age was associated with higher concentrations of sex hormone-binding globulin and dihydrotestosterone and lower concentrations of dehydroepiandrosterone sulfate, free testosterone, androstenedione, androstanediol glucuronide and free estradiol. Higher body mass index was associated with higher concentrations of free estradiol, androstanediol glucuronide, estradiol and estrone and lower concentrations of dihydrotestosterone, testosterone, sex hormone-binding globulin, free testosterone, androstenedione and dehydroepiandrosterone sulfate. Taller height was associated with lower concentrations of androstenedione, testosterone, free testosterone and sex hormone-binding globulin and higher concentrations of androstanediol glucuronide. Current smoking was associated with higher concentrations of androstenedione, sex hormone-binding globulin and testosterone. Alcohol consumption was associated with higher concentrations of dehydroepiandrosterone sulfate, androstenedione and androstanediol glucuronide. East Asians had lower concentrations of androstanediol glucuronide and African Americans had higher concentrations of estrogens. Education and marital status were modestly associated with a small number of hormones. CONCLUSION: Circulating sex hormones in men are strongly associated with age and body mass index, and to a lesser extent with smoking status and alcohol consumption.


Subject(s)
Anthropometry , Behavior , Datasets as Topic , Gonadal Steroid Hormones/blood , Social Class , Adult , Humans , Male , Young Adult
3.
Nucl Med Commun ; 38(5): 357-365, 2017 May.
Article in English | MEDLINE | ID: mdl-28338529

ABSTRACT

OBJECTIVE: The aim of this work is to validate a software package called Hermes Internal Radiation Dosimetry (HIRD) for internal dose assessment tailored for clinical practice. The software includes all the necessary steps to perform voxel-level absorbed dose calculations including quantitative reconstruction, image coregistration and volume of interest tools. METHODS: The basics of voxel-level dosimetry methods and implementations to HIRD software are reviewed. Then, HIRD is validated using simulated SPECT/CT data and data from Lu-DOTATATE-treated patients by comparing absorbed kidney doses with OLINDA/EXM-based dosimetry. In addition, electron and photon dose components are studied separately in an example patient case. RESULTS: The simulation study showed that HIRD can reproduce time-activity curves accurately and produce absorbed doses with less than 10% error for the kidneys, liver and spleen. From the patient data, the absorbed kidney doses calculated using HIRD and using OLINDA/EXM were highly correlated (Pearson's correlation coefficient, r=0.98). From Bland-Altman plot analysis, an average absorbed dose difference of -2% was found between the methods. In addition, we found that in Lu-DOTATATE-treated patients, photons can contribute over 10% of the kidney's total dose and is partly because of cross-irradiation from high-uptake lesions close to the kidneys. CONCLUSION: HIRD is a straightforward voxel-level internal dosimetry software. Its clinical utility was verified with simulated and clinical Lu-DOTATATE-treated patient data. Patient studies also showed that photon contribution towards the total dose can be relatively high and voxel-level dose calculations can be valuable in cases where the target organ is in close proximity to high-uptake organs.


Subject(s)
Image Processing, Computer-Assisted , Radiation Dosage , Radiometry/methods , Software , Humans , Kidney/diagnostic imaging , Phantoms, Imaging , Retrospective Studies , Single Photon Emission Computed Tomography Computed Tomography
4.
Acta Oncol ; 55(3): 357-64, 2016.
Article in English | MEDLINE | ID: mdl-26339947

ABSTRACT

Background Total thyroidectomy is the treatment of choice for medullary thyroid carcinoma (MTC), but the extent of neck dissection is controversial. Lymph node metastases, distant metastases, and old age are known predictors of poor survival. Patients Patients treated for primary MTC at Helsinki University Hospital from 1990 to 2009 were included (n = 54). Their clinical characteristics, treatment, and outcome were analysed retrospectively, these patients were followed until death or their last follow-up date. Results At last follow-up (3.4-23 years), of 54 MTC patients, 19 (35%) were disease-free, 17 (32%) were alive with disease, and 12 (22%) had died of MTC; six patients died of unrelated causes (11%). All disease-free patients were node negative and had normal postoperative calcitonin level. Of 19 disease-free patients, only four (21%) had undergone lymph node dissection. All patients who died of MTC were Stage IV at diagnosis and died with distant metastases. Disease-specific five-and 10-year survival was 84% and 76.2%. Advanced T-stage (p = 0.004), lymph node metastases (p < 0.001), distant metastases (p < 0.001), stage (p < 0.001), and elevated postoperative calcitonin (p < 0.001) significantly associated with survival. Conclusions Lymph node metastasis and elevated postoperative calcitonin are important prognostic factors. Patients with lymph node metastasis and/or elevated postoperative calcitonin with present treatments cannot become disease-free, but most of them can live a long life with metastasis.


Subject(s)
Biomarkers, Tumor/metabolism , Calcitonin/metabolism , Carcinoma, Medullary/mortality , Neoplasm Recurrence, Local/mortality , Postoperative Complications/diagnosis , Thyroid Neoplasms/mortality , Thyroidectomy/adverse effects , Adult , Carcinoma, Medullary/metabolism , Carcinoma, Medullary/secondary , Female , Follow-Up Studies , Humans , Immunoenzyme Techniques , Lymph Node Excision , Lymphatic Metastasis , Male , Middle Aged , Neoplasm Recurrence, Local/metabolism , Neoplasm Recurrence, Local/pathology , Neoplasm Staging , Postoperative Complications/etiology , Postoperative Complications/metabolism , Prognosis , Retrospective Studies , Survival Rate , Thyroid Neoplasms/metabolism , Thyroid Neoplasms/pathology
5.
Duodecim ; 126(20): 2424-30, 2010.
Article in Finnish | MEDLINE | ID: mdl-21125756

ABSTRACT

While papillary and follicular thyroid cancer usually has an excellent prognosis, recurrent and aggressive forms of the disease do occur. The success of surgical excision and radioiodine therapy is evaluated by ultrasonography of the neck, and TSH-stimulated serum thyreoglobulin. Based on investigational results, the patients are divided into three groups: the cancer does not exist, may exist or remains. This classification determines the thyroxine dose and follow-up arrangements. In cancer-free patients, thyroxine therapy will be implemented as in ordinary hypothyreoidism. For others a thyroxine dose will be used that lowers the serum TSH below reference values.


Subject(s)
Carcinoma, Papillary/radiotherapy , Carcinoma, Papillary/surgery , Iodine Radioisotopes/therapeutic use , Ablation Techniques , Adenocarcinoma, Follicular , Combined Modality Therapy , Disease-Free Survival , Hormone Replacement Therapy , Humans , Thyroid Neoplasms/radiotherapy , Thyroid Neoplasms/surgery , Thyroxine/therapeutic use
6.
Duodecim ; 126(14): 1669-75, 2010.
Article in Finnish | MEDLINE | ID: mdl-20804085

ABSTRACT

The prognosis of glioma has improved. Even patients with glioblastoma surviving over two years is not rare. The quality of life has improved because of earlier diagnosis and more precise surgical and radiotherapy techniques. In grade 3-4 gliomas treatment modalities are combined. In grade 2 there are several options for postoperative treatment. Recurrencies are treated actively irrespective of the initial histological grade of the tumor. Chemotherapy is used both combined with radiotherapy and as a single treatment at recurrence. The best results are achieved with close co-operation among different specialities in neuro-oncology, most effectively in weekly meetings. Fluent flow of information between health care units promotes the best quality of life for glioma patients.


Subject(s)
Brain Neoplasms/therapy , Glioma/therapy , Adult , Brain Neoplasms/diagnosis , Brain Neoplasms/pathology , Combined Modality Therapy , Early Diagnosis , Glioma/diagnosis , Glioma/pathology , Humans , Neoplasm Recurrence, Local/therapy , Neoplasm Staging , Patient Care Planning/organization & administration , Prognosis , Quality of Life , Survival Rate
7.
PLoS One ; 3(4): e1885, 2008 Apr 02.
Article in English | MEDLINE | ID: mdl-18382668

ABSTRACT

BACKGROUND: Radioactive iodine is commonly administered following thyroidectomy for differentiated thyroid carcinoma to ablate the thyroid remnant. The optimal administered activity of radioiodine is unknown. METHODOLOGY/PRINCIPAL FINDINGS: Adult subjects (n = 160) diagnosed with papillary or follicular thyroid carcinoma were randomly allocated to receive either 1100 MBq (30 mCi) or 3700 MBq (100 mCi) activity of radioiodine ((131)I) following thyroidectomy. The study participants were prepared for ablation using thyroid hormone withdrawal. Ablation was considered successful when serum thyroglobulin concentration was less than 1 ng/mL and no uptake was present in (131)I scan. Ablation was successful following one administration of radioiodine in 42 (52%; 95% CI, 41% to 63%) of the 81 evaluable study participants who received 1100 MBq, and in 43 (56%, 45% to 67%) of the 77 subjects who received 3700 MBq activity (P = .61). There was no difference between the groups in the numbers of repeat radioiodine treatments needed to complete ablation (P = .27). The higher activity was associated with more nausea and taste disturbances, and a longer stay in a radioprotected isolation unit. None of the participants died from thyroid cancer during a median follow up of 51 months; three subjects in the 3700 MBq group and none in the 1100 MBq group were diagnosed with distant metastases during follow-up. In a meta-analysis of four randomized studies that compared the 1100 and 3700 MBq activities, the 1100 MBq activity tended to be associated with a higher risk of unsuccessful ablation (relative risk 1.148, 95% CI 0.974 to 1.353, P = .10). CONCLUSIONS/SIGNIFICANCE: The results provide no conclusive evidence that 3700 MBq activity is more effective for ablation of the thyroid remnant than 1100 MBq activity. The 3700 MBq activity is associated with more adverse effects. TRIAL REGISTRATION: ClinicalTrials.gov NCT00115895.


Subject(s)
Iodine Radioisotopes/therapeutic use , Thyroid Gland/radiation effects , Thyroid Neoplasms/radiotherapy , Thyroidectomy/methods , Adult , Aged , Aged, 80 and over , Female , Humans , Lymphatic Metastasis , Male , Middle Aged , Recurrence , Time Factors , Treatment Outcome
8.
Acta Oncol ; 43(6): 579-84, 2004.
Article in English | MEDLINE | ID: mdl-15370616

ABSTRACT

Thirty-two patients with relapsing glioma were treated with temozolomide in two university hospitals in Finland. One patient (3%) had complete response and 9 (28%) partial response, with 8 patients (25%) showing stable disease. Median progression-free survival for these 18 patients (56%) was 7 months (range 2-11+). The remaining either had progressive disease (25%) or only clinical evaluation (19%). Karnofsky score improved in 34% of patients and decreased in 3%. Symptoms were alleviated in 44% and deteriorated in 9%. Grade 3-4 toxicity was detected in 9% of the patients. Only 4% of the days in treatment were spent in hospital. An average 1.8 neuroradiological investigations, 6.9 laboratory visits, and 5.3 visits to the oncologist were made. This study confirms that temozolomide has positive effects on the outcome of often heavily pretreated glioma patients. High drug costs are compensated by prolonged home care and even the possibility to maintain working capacity.


Subject(s)
Antineoplastic Agents, Alkylating/therapeutic use , Brain Neoplasms/drug therapy , Dacarbazine/analogs & derivatives , Dacarbazine/therapeutic use , Glioma/drug therapy , Adult , Aged , Antineoplastic Agents, Alkylating/adverse effects , Antineoplastic Agents, Alkylating/economics , Cost-Benefit Analysis , Dacarbazine/adverse effects , Dacarbazine/economics , Disease-Free Survival , Drug Costs , Female , Humans , Male , Middle Aged , Temozolomide , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL